TKT Genericizes Proteins

Following its failed 1993 IPO, TKT embarked on a strategy to develop and market through a larger partner competing versions of top-selling protein drugs. The company's first target: EPO, which currently generates more than $3.3 billion for Amgen annually. EPO and other protein drugs still have several years of patent protection left, but TKT believes it's found a way around those patents with a production process called gene activation.